ClassID:

112319

C12N2840/007 - CPC Classification

Classification description:

Vectors comprising a special translation-regulating system cell or tissue specific

Recent Application in this class:
#1
20260085102
2026-03-26

TISSUE SPECIFIC SYNTHETIC PROMOTERS AND CIRCUITS AND USE THEREOF

#2
20260078404
2026-03-19

COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATION

#3
20260035714
2026-02-05

ENGINEERED POLYNUCLEOTIDES FOR CELL SELECTIVE EXPRESSION

#4
20260022356
2026-01-22

NPP1 Fusion Proteins

#5
20260000787
2026-01-01

METHODS OF TREATING NON-SYNDROMIC SENSORINEURAL HEARING LOSS

#6
20250304975
2025-10-02

APTAMER AND RIBOZYME EQUILIBRIUM SHIFTING (ARES) RNA CIRCUITS AND USES THEREOF

#7
20250295733
2025-09-25

Compositions for Treating Pathological Calcification Conditions, and Methods Using Same

#8
20250161384
2025-05-22

TRANSCRIPTIONAL AND TRANSLATIONAL DUAL REGULATED ONCOLYTIC HERPES SIMPLEX VIRUS VECTORS

#9
20250084434
2025-03-13

VECTOR CONSTRUCTS FOR DELIVERY OF NUCLEIC ACIDS ENCODING THERAPEUTIC ANTI-IGF-1R ANTIBODIES AND METHODS OF USING THE SAME

#10
20250082723
2025-03-13

METHODS AND COMPOSITIONS RELATING TO THE TREATMENT OF TUMORS

#11
20250019722
2025-01-16

COMPOSITIONS COMPRISING KOZAK SEQUENCES SELECTED FOR ENHANCED EXPRESSION

#12
20250019674
2025-01-16

PROTEIN DEGRADATION SYSTEM, COMPONENTS, AND METHODS

#13
20240229075
2024-07-11

IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION

#14
20240189455
2024-06-13

COMPOSITIONS AND METHODS FOR TREATING RIGHT VENTRICLE DYSFUNCTION

#15
20240100188
2024-03-28

REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF

#16
20240016132
2024-01-18

Gene Expression System

#17
20230357436
2023-11-09

ANTI-IDIOTYPE COMPOSITIONS AND METHODS OF USE THEREOF

#18
20230348862
2023-11-02

IMMUNOENGINEERED PLURIPOTENT CELLS

#19
20230332179
2023-10-19

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#20
20230287366
2023-09-14

GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A

#21
20230279431
2023-09-07

Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy

#22
20230220422
2023-07-13

FUSOGENIC LIPID NANOPARTICLES AND METHODS FOR THE MANUFACTURE AND USE THEREOF FOR THE TARGET CELL-SPECIFIC PRODUCTION OF A THERAPEUTIC PROTEIN AND FOR THE TREATMENT OF A DISEASE, CONDITION, OR DISORDER ASSOCIATED WITH A TARGET CELL

#23
20230073187
2023-03-09

PROSTATE TARGETING ADENO-ASSOCIATED VIRUS SEROTYPE VECTORS

#24
20220325249
2022-10-13

PLATFORM FOR THE INDUCTION & MAINTENANCE OF GROUND STATE PLURIPOTENCY

#25
20220213172
2022-07-07

VIRAL VECTORS ENCODING RECOMBINANT FVIII VARIANTS WITH INCREASED EXPRESSION FOR GENE THERAPY OF HEMOPHILIA A

#26
20220193263
2022-06-23

REGULATABLE ADENO-ASSOCIATED VIRUS (AAV) VECTOR

#27
20220162640
2022-05-26

HYBRID PROMOTERS FOR MUSCLE EXPRESSION

#28
20220136009
2022-05-05

COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATION

#29
20220133854
2022-05-05

Compositions for treating pathological calcification conditions, and methods using same

#30
20210330816
2021-10-28

GENE THERAPY FOR OCULAR DISORDERS

#31
20210330814
2021-10-28

Methods of treating non-syndromic sensorineural hearing loss

#32
20210269826
2021-09-02

PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN MÜLLER CELLS

#33
20210260217
2021-08-26

GENERATING GABAergic NEURONS IN BRAINS

#34
20210205476
2021-07-08

Isolation of novel AAV's and uses thereof

#35
20210188927
2021-06-24

COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION

#36
20210137083
2021-05-13

Gene expression system

#37
20210095310
2021-04-01

MICRORNA REGULATED EXPRESSION VECTORS, METHODS OF MAKING, AND USES THEREOF

#38
20200405810
2020-12-31

Efficient systemic treatment of dystrophic muscle pathologies

#39
20200237865
2020-07-30

Methods for treating pseudoxanthoma elasticum (PXE)

#40
20200157568
2020-05-21

EXPRESSION VECTORS AND RELATED METHODS OF DELIVERY OF Na/K ATPASE/Src RECEPTOR COMPLEX ANTAGONISTS

#41
20200149054
2020-05-14

Compositions and methods of dual poison-antidote meiotic drivers

#42
20200140831
2020-05-07

Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy

#43
20200138905
2020-05-07

Compositions for treating pathological calcification conditions, and methods using same

#44
20200113955
2020-04-16

MODIFIED UBE3A GENE FOR A GENE THERAPY APPROACH FOR ANGELMAN SYNDROME

#45
20200080066
2020-03-12

GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A

#46
20200061209
2020-02-27

Gene therapy for ocular disorders

#47
20200017868
2020-01-16

Compositions and methods for improving plastid transformation efficiency in higher plants

#48
20200016278
2020-01-16

Stable gene transfer to proliferating cells

#49
20190376045
2019-12-12

IMMUNOENGINEERED PLURIPOTENT CELLS

#50
20190365926
2019-12-05

Polynucleotides and vectors for the expression of transgenes

#51
20190336577
2019-11-07

Methods and compositions relating to the treatment of tumors

#52
20190330657
2019-10-31

Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof

#53
20190282709
2019-09-19

Isolation of novel AAV's and uses thereof

#54
20190276849
2019-09-12

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#55
20190276848
2019-09-12

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#56
20190247452
2019-08-15

Tumor-specific adenovirus vectors and therapeutic uses

#57
20190231849
2019-08-01

Compositions for treating pathological calcification conditions, and methods using same

#58
20190218520
2019-07-18

Platform for the induction and maintenance of ground state pluripotency

#59
20190202893
2019-07-04

Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

#60
20190194689
2019-06-27

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#61
20190194688
2019-06-27

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#62
20190194295
2019-06-27

Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

#63
20190167762
2019-06-06

Efficient systemic treatment of dystrophic muscle pathologies

#64
20190024121
2019-01-24

TISSUE SELECTIVE TRANSGENE EXPRESSION

#65
20190024120
2019-01-24

Tissue selective transgene expression

#66
20190024119
2019-01-24

Tissue selective transgene expression

#67
20190024118
2019-01-24

Tissue selective transgene expression

#68
20180311380
2018-11-01

Prostate-targeting adeno-associated virus serotype vectors

#69
20180244738
2018-08-30

Tumor suppressor SALL1 as a therapeutic agent for treating cancer

#70
20180179550
2018-06-28

Plants having increased tolerance to herbicides

#71
20180148738
2018-05-31

CNS TARGETING AAV VECTORS AND METHODS OF USE THEREOF

#72
20180127778
2018-05-10

Promoter for the specific expression of genes in Müller cells

#73
20180064786
2018-03-08

Compositions for treating pathological calcification conditions, and methods using same

#74
20180057821
2018-03-01

Compositions for treating pathological calcification conditions, and methods using same

#75
20180057820
2018-03-01

Compositions for treating pathological calcification conditions, methods, and host cells using the same

#76
20170362605
2017-12-21

TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES

#77
20170349911
2017-12-07

CNS targeting AAV vectors and methods of use thereof

#78
20170340714
2017-11-30

Compositions for treating pathological calcification conditions, and methods using same

#79
20170340713
2017-11-30

Compositions for treating pathological calcification conditions, and methods using same

#80
20170304464
2017-10-26

REGULATABLE ADENO-ASSOCIATED VIRUS (AAV) VECTOR

#81
20170239373
2017-08-24

Generating GABAergic neurons in brains

#82
20170233456
2017-08-17

Expression cassette for packaging and expression of variant factor VIII for the treatment of hemostasis disorders

#83
20170233455
2017-08-17

Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

#84
20170226188
2017-08-10

Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

#85
20170218398
2017-08-03

METHOD TO SELECTIVELY TARGET CANCEROUS CELLS FOR GENETIC MANIPULATION

#86
20170216456
2017-08-03

Stable Gene Transfer to Proliferating Cells

#87
20170188559
2017-07-06

GENE EXPRESSION SYSTEM

#88
20170166927
2017-06-15

Isolation of novel AAV's and uses thereof

#89
20170165377
2017-06-15

Isolation of novel AAV's and uses thereof

#90
20170157213
2017-06-08

Efficient systemic treatment of dystrophic muscle pathologies

#91
20170145393
2017-05-25

NPP1 FUSION PROTEINS

#92
20160281107
2016-09-29

Synthetic regulation of gene expression

#93
20150079682
2015-03-19

Non-viral episomal suicide construct

#94
20150037290
2015-02-05

Methods of modulating smooth muscle cell proliferation and differentiation

#95
20140366217
2014-12-11

Alpha amylase mutant inhibitors isolated from phaseolus vulgaris with properties of controlling insect pests, compositions containing such mutants, and method of using thereof

#96
20140335054
2014-11-13

CNS targeting AAV vectors and methods of use thereof

#97
20130254909
2013-09-26

Synthetic regulation of gene expression

#98
20130195801
2013-08-01

CNS targeting AAV vectors and methods of use thereof

#99
20120093789
2012-04-19

Methods of modulating smooth muscle cell proliferation and differentiation

#100
20110237652
2011-09-29

Detection and destruction of cancer cells using programmed genetic vectors

#101
20100186103
2010-07-22

Isolation of novel AAV'S and uses thereof

#102
20090217394
2009-08-27

Diabetes Model Animal

#103
20090187997
2009-07-23

Cre-lox based gene knockdown constructs and methods of use thereof

#104
20090117156
2009-05-07

GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A

#105
20080075721
2008-03-27

Method of treating fibrosis

#106
20070275915
2007-11-29

Tmprss2 Regulatory Sequences and Uses Thereof

#107
20070053909
2007-03-08

METHOD OF TREATING FIBROSIS

#108
20050049218
2005-03-03

Method for treating fibrosis